Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 03-17-2004, 09:55 AM   #1
Posts: n/a
In the longest prospective clinical trial ever conducted in the treatment of postmenopausal osteoporosis -- a chronic condition that can lead to bone loss and susceptibility to fractures -- researchers found that postmenopausal women taking FOSAMAX(R) (alendronate sodium) maintained or continued to experience increases in bone mineral density (BMD) at the hip and spine through 10 years of treatment. Results from the trial were published today in the New England Journal of Medicine. FOSAMAX is the only medicine approved by the Food and Drug Administration in the treatment of osteoporosis to increase BMD and reduce the incidence of both spine and hip fractures in postmenopausal women.

  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 04:09 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter